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Abstract
Epidemiological data support the hypothesis that environmental and occupational agents play
an important role in the development of interstitial lung diseases such as idiopathic interstitial
pneumonia (IIPs) and sarcoidosis. The aim of this study was to assess the elemental
composition of exhaled breath condensate (EBC) in patients with interstitial lung diseases
(ILDs) of unknown etiology and healthy subjects as an indirect evaluation of tissue burden,
which could improve our understanding of the role of metals in the pathogenesis of ILDs.
EBC was obtained from 33 healthy subjects, 22 patients with sarcoidosis, 15 patients with
non-specific interstitial pneumonia (NSIP) and 19 with IIPs. Trace elements and toxic metals
in the samples were measured by means of inductively coupled plasma-mass spectrometry.
There are only small overall differences in the EBC levels of a number of metallic elements
among patients with idiopathic pulmonary fibrosis (IPF), NSIP or sarcoidosis, and no pattern
is capable of distinguishing them with a high degree of sensitivity and specificity. However, a
pattern of pneumotoxic (Si, Ni) and essential elements (Zn, Se and Cu) with the addition of Co
distinguished the patients with ILDs from healthy non-smokers with relatively high degrees of
sensitivity (96.4%) and specificity (90.9%). Assessing the elemental composition of EBC in
patients with different ILDs seems to provide useful information. The non-invasiveness of the
EBC method makes it suitable for patients with pulmonary diseases, although further studies
are required to confirm the usefulness of this approach and to better understand the underlying
pathophysiological processes.
(Some figures in this article are in colour only in the electronic version)
Introduction
Interstitial lung diseases (ILDs) are a heterogenic group of
disorders characterized by inflammation and fibrosis involving
the pulmonary interstitium and parenchyma [1, 2] in which
structural alterations lead to progressive breathlessness, lung
crackles and diffusely abnormal chest radiography findings
[1, 3]. Their pathogenesis is complex: each disorder has
a different histopathological pattern with varying degrees of
inflammation and fibrosis, typical radiographic features upon
high resolution computed tomography (HRCT) scanning and
a variable clinical course.
Idiopathic interstitial pneumonia (IIPs) and sarcoidosis
seem to be the most frequent ILDs [4, 5]. The most common
IIPs are idiopathic pulmonary fibrosis (IPF) and non-specific
interstitial pneumonia (NSIP), which can be distinguished
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from the other forms of diffuse parenchymal lung disease
on the basis of clinical, radiological and pathological criteria
[2]. Sarcoidosis is a systemic granulomatous disease with
predilection for lung and the lymphoid system [6, 7].
The etiology of most ILDs is still unknown, but probably
includes genetic factors, host susceptibility and exposure to
specific environmental factors, as well as interactions between
them [8, 9]. Epidemiological data support the hypothesis
that environmental and occupational agents play an important
role in the development of IPF and sarcoidosis [10]. There
is a significant association between an increased risk of IPF
and exposure to cigarette smoking, metal and wood dust, stone
sand, and farming and livestock [11–16], and people employed
in agriculture or by suppliers of hardware and building and
gardening materials, or exposed to wood or organic dust, are at
increased risk for sarcoidosis. Metal dusts and fumes, musty
odors, microbial-rich environments and smoking are either
occupational or environmental risk factors for sarcoidosis
[10, 17, 18].
Further information about the role of metallic elements in
the development of these diseases can be obtained by assessing
lung metal burden. Biological samples can be collected using
invasive methods such as lung biopsy (which clearly cannot
be proposed for research purposes), bronchoalveolar lavage
(BAL), which allows the direct sampling of material from the
lower respiratory tract, or exhaled breath condensate (EBC)
obtained by cooling exhaled air.
EBC is a biological matrix that seems to be representative
of the composition of airway lining fluid and can therefore be
used to assess biomarkers of exposure, effect and susceptibility
in patients with lung diseases or subjects exposed to ambient
pollutants [19–25]. Unlike BAL, it is also simple to collect
and totally non-invasive, thus making it suitable for research
studies. We have recently proposed using the elemental
analysis of EBC as a means of deriving specific pulmonary
levels of pneumotoxic or essential transition elements by
considering exhaled metals as a quantitative estimate of the
target tissue burden [21, 26].
The aim of this study was to assess the elemental
composition of EBC in patients with ILDs of unknown
etiology and healthy subjects as an indirect evaluation of
tissue burden, which could improve our understanding of
the role of metals in the pathogenesis of ILDs. We also
investigated whether the EBC levels of several metals may
be useful in distinguishing ILD patients from healthy subjects.
Furthermore, EBC levels of transition elements could be used
as biomarkers of susceptibility given their role in oxidant/anti-
oxidant balance and the fact that oxidative stress seems to
contribute to the pathophysiology of ILDs [27–29].
Materials and methods
Study population
The patients with IPF, NSIP or sarcoidosis were recruited
at Parma Hospital’s Outpatient Clinic of Interstitial Lung
Diseases; the control group consisted of healthy non-smokers
who were not occupationally exposed to metals.
The study was approved by the Ethics Committee of the
University of Parma and was conducted in conformity with
the Declaration of Helsinki. All of the subjects gave their
informed written consent to participate.
IPF and NSIP were diagnosed on the basis of
clinical, radiological and histological findings using the
ATS/ERS international consensus criteria [2, 30]; sarcoidosis
was diagnosed on the basis of clinical and radiological
findings supported by histological evidence of non-caseating
epithelioid cell granulomas [31, 32].
Methods
All of the study subjects (patients and controls) underwent the
administration of a medical questionnaire, lung function tests
and EBC collection.
Tobacco smoke exposure was evaluated in terms of self-
reported current smoking status, with the number of cigarettes
smoked per day and the number of years of smoking being
recorded. Patients who had stopped smoking at least 1 year
before recruitment were defined ex-smokers.
All of the subjects underwent spirometry, assessment of
total lung capacity (TLC) and the measurement of single-
breath diffusing lung capacity for carbon monoxide (DLCO)
using a flow-sensing spirometer and a body plethysmograph
(Vmax, SensorMedics, USA) connected to a computer for data
analysis.
EBC was collected using a portable condenser (TURBO-
DECCS; Medivac, Parma, Italy) at a collecting constant
temperature of −5 ◦C as previously described [21]. Subjects
were asked to breathe normally for 15 min and EBC collection
was performed after at least 1 h of rest and all the samplings
were done in the same room. EBC samples were stored at
−80 ◦C until transport in dry ice to the laboratory of Brescia
(Italy) for analysis, where their elemental composition was
determined by means of inductively coupled plasma mass
spectrometry (ICP-MS; ELAN 5000, Perkin Elmer, Wellesley,
MA) as previously described [21, 33]. Only the metallic
elements with measurable levels in 33% of the EBC samples
were recorded; the ICP-MS limit of detection (LOD) of metals
was 0.005 μg L−1. The intrasubject variability is an average
of 20–30% for the metals reported in this study.
Statistics
The data were statistically analysed by means of Prism 4
(GraphPad; San Diego, CA) and SPSS 16.0 software (SPSS;
Chicago, IL). Non-parametric tests were used, as the data
significantly deviated from normality. The groups (IPF, NSIP,
sarcoidosis and controls) were compared using the Kruskal–
Wallis test followed by Dunn’s test for multiple comparisons.
The correlations between variables were assessed using
Spearman’s rank correlation. Multinomial and binary logistic
regression was used to assess whether the groups were
distinguishable, with group codes as the dependent variable
and metal concentrations as predictors. The predicted
probabilities of belonging to a group obtained using logistic
regression were entered in a receiving operating curve (ROC)
analysis in order to evaluate whether EBC concentrations of
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Table 1. Characteristics of study subjects.
IPF NSIP Sarcoidosis Controls
No of subjects (M/F) 19 (14/5) 15 (9/6) 22 (14/8) 33 (25/8)
Age 68 ± 0.78 65.3 ± 9.7 53.5 ± 13.9 55 ± 10.80
Ex/non-smokers 13/6 10/5 16/6 0/33
Pack/years 24.5 (16.5–38.5) 26.4 (15.0–42.5) 16.5 (5.3–20.0) 0
FEV1 L 1.93 ± 0.8 2.02 ± 07 2.7 ± 1.5 3.7 ± 2
FEV1% of predicted 71.2 ± 1.2 71.7 ± 0.4 83.9 ± 2.4 117.3 ± 1
FVC, L 2.3 ± 0.9 2.6 ± 0.9 3.5 ± 0.9 4.8 ± 0.9
FVC% of predicted 67.8 ± 19.2 80.8 ± 18.1 94 ± 12.5 108 ± 10.5
TLC, L 3.8 ± 1.2 4.4 ± 1.4 5.4 ± 1.1 5.6 ± 1.3
TLC% of predicted 62.0 ± 13.5 75.2 ± 16.4 89.6 ± 11.4 85 ± 2.3
FEV1/FVC% 84.1±7.4 78.8 ± 8.6 79.7 ± 7.8 79 ± 7.4
DLCO% of predicted 46.4 ± 17.6 59.7 ± 19.5 76.3 ± 18.8 81 ± 17.1
Mean values ± SD, or median values (25th–75th percentile).
IPF: idiopathic pulmonary fibrosis; NSIP: non-specific interstitial pneumonia; FVC: forced
vital capacity; TLC: total lung capacity, DLCO%: diffusing lung capacity for carbon monoxide.
Table 2. Metallic elements in exhaled breath condensate of patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial
pneumonia (NSIP) or sarcoidosis, and controls.
Metals (μg L−1) IPF (n = 19) NSIP (n = 15) Sarcoidosis (n = 22) Controls (n = 33)
Al 1.8 (0.72–2.50) 1.6 (1.2–3.3) 1.6 (1.2–2.08) 1.2 (0.60–2.35)
Pb 0.04 (ND–0.13) 0.03 (ND–0.09) 0.04 (ND–0.1) 0.02 (0.008–0.055)
Ni 0.40 (0.3–0.6)∗ 0.5 (0.3–0.8)∗ 0.40 (0.31–0.6)∗ 0.20 (0.08–0.40)
Cr 0.05 (0.03–0.20)∗ 0.1 (0.03–1.1)∗ 0.07 (0.04–0.28)∗ ND (ND–0.015)
Si 66 (38–140)∗ 87 (59–146)∗ 59 (41–92.5)∗ 19 (0.5–47)
Co ND (ND–0.008)∗ 0.01 (ND–0.01) ND (ND–0.01)∗ 0.01 (ND–0.025)
Ca 41 (29–49) 23 (16–82) 47 (25–75.7) 63 (38–243)
Zn 2.1 (ND–6.6) 0.6 (ND–3.5) 0.22 (ND–2.1)∗ 1.6 (0.50–22)
Fe 0.30 (0.20–0.50)∗ 0.30 (0.20–0.40)∗ 0.35 (0.21–0.9) 1.20 (0.25–6.00)
Cu 0.10 (ND–0.4)∗ 0.01 (ND–0.40)∗ 0.25 (ND–0.48)∗ 0.60 (0.30–1.80)
Se ND∗ ND (ND–0.05)∗ ND (ND–0.1)∗ 0.30 (0.10–1.20)
Mn 0.17 (0.10–0.30) 0.20 (0.12–0.28) 0.23 (0.09–0.3) 0.10 (0.04–0.25)
Mo ND (ND–0.02)∗ 0.02 (ND–0.05) 0.01 (ND–0.03) 0.03 (0.01–0.08)
Median values (25th–75th percentile); ND: not determinable.
∗ p < 0.05 versus controls.
the metallic elements are useful in distinguishing controls and
ILD patients. A significance level of 0.05 was used for all of
the statistical tests.
Results
We initially recruited 61 patients with IPF, NSIP or sarcoidosis
attending Parma Hospital’s Outpatient Clinic of Interstitial
Lung Diseases, and 33 healthy controls who were all non-
smokers and not occupationally exposed to metals. However
five patients were smokers (2/17 with NSIP and 3/25 with
sarcoidosis patients) and were excluded from the analysis. As
no differences were found between the ex-smokers and non-
smokers with different ILDs, we did not consider being an
ex-smoker a confounding factor.
We performed some experiments with non-smokers
(no 5) where EBC was collected before and after having
smoked a single cigarette. These are the results on the most
important metals related to smoking habits in the literature (Pb,
Ni, Cr, Al, Cd). Cr and Cd were always below LOD. Pb passed
from 0.04 (range: ND–0.07) to 0.04 (0.02–0.08) μg L−1;
Ni passed from 0.21 (0.09–0.30) to 0.20 (0.15–0.32) μg L−1;
Al passed from 1.8 (0.7–2.2) to 1.7 (1.5–2.3) μg L−1.
Table 1 shows the characteristics of the study subjects.
The results of the lung function tests showed that the
patients with IPF and NSIP had a reduced TLC compatible
with restrictive ventilatory defect (TLC < 80%), whereas
the patients with sarcoidosis had normal spirometric and
plethysmographic values. All of the patients had decreased
DLCO% values, but both DLCO% and TLC were lower in the
patients with IPF (median 46.4% and 3.8 L) than in those with
sarcoidosis (76.3% and 5.4 L) (p < 0.001).
The volume of EBC did not differ between patients and
controls and age was not correlated with EBC metallic values.
Table 2 shows the metallic and trace elements determined
in the EBC samples. Some metals were below the LOD in
more than 50% of cases: Cd in all groups; Co and Se in all of
the patients; and Mo in the IPF group. In these cases, a level
of half the LOD was arbitrarily assumed.
The EBC levels of some of the metallic elements
considered to be pneumotoxic (Cr, Ni, Si) were higher in all
patient groups than in the controls (figure 1), whereas those of
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Figure 1. Ni, Cr and Si levels in EBC samples of patients with
idiopathic pulmonary fibrosis (IPF), non-specific interstitial
pneumonia (NSIP) or sarcoidosis (S), and controls (CTR)
Co were higher in the controls than in the IPF and sarcoidosis
patients (table 2).
The transition elements that play an important role in
the oxidant/anti-oxidant balance and are co-factors of various
enzymes showed various trends: Cu and Se levels were higher
in the controls than in all the patient groups (figure 2), and
Fe levels were higher in the controls than in the IPF and
NSIP patients (figure 2). Finally, Zn levels were higher in
the controls than in the patients with sarcoidosis (table 2), and
Mo levels were higher in the controls than in the IPF patients
(table 2). The differences in the levels of the remaining
metallic elements were not significant.
There was a positive correlation between EBC Fe levels
and DLCO in the patients with sarcoidosis (r = 0.46 p <
0.05) (figure 3(A)), and between EBC Fe levels and TLC in
the IPF patients (r = 0.53; p < 0.05) (figure 3(B)). No other
correlations were found between lung function parameters and
EBC metallic elements.
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Figure 2. Cu, Fe and Se levels in EBC samples of patients with
idiopathic pulmonary fibrosis (IPF), non-specific interstitial
pneumonia (NSIP) or sarcoidosis (S), and controls (CTRL).
A multinomial logistic regression model was first used to
classify the IPF/NSIP patients, the patients with sarcoidosis
and controls on the basis of the pattern of metallic elements in
their EBC. Co, Mo, Ni, Cr, Si, Fe, Cu, Se and Zn were included
in the model because of their significance in the comparisons;
the other elements were excluded. Zn (p = 0.035), Si (p =
0.014), Ni (p = 0.002) and Se (p = 0.009) distinguished the
controls from the IPF/NSIP patients, and Co (p = 0.015), Ni
(p = 0.002) and Se (p = 0.043) distinguished the controls
from the patients with sarcoidosis (table 3(A)). However, the
classification table (table 3(B)) showed that the controls were
correctly classified in 87.9% of cases (29/33), whereas there
was an overlap between the sarcoidosis and IPF/NSIP groups
in 63.6% of cases (14/22).
The analysis was therefore repeated considering all of the
ILDs together and using binary logistic regression (table 4).
This model identified Co (p = 0.015), Zn (p = 0.029),
Si (p = 0.026), Ni (p = 0.002) and Se (p = 0.021) as
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Table 3. (A) Classification of cases by means of multinomial logistic regression analysis. The patients with IPF or NSIP were considered as
a single group. (B) The significance of each metallic element estimated by means of multinomial logistic regression analysis, with controls
as the reference category.
(A)
Predicted
Observed IPF/NSIP Sarcoidosis Controls Percent correct
IPF/NSIP 28 3 3 82.4%
Sarcoidosis 14 8 0 36.4%
Controls 2 2 29 87.9%
(B)
0 = IPF and NSIP;
1 = sarcoidosis;
2 = controlsa Significance
0 = IPF and NSIP; 1 =
sarcoidosis;
2 = controlsa Significance
0.00 Intercept 0.303 1.00 Intercept 0.246
Co 0.044 Co 0.015
Mo 0.626 Mo 0.171
Zn 0.035 Zn 0.055
Cu 0.065 Cu 0.061
Si 0.014 Si 0.102
Fe 0.418 Fe 0.653
Cr 0.765 Cr 0.908
Ni 0.002 Ni 0.002
Se 0.009 Se 0.043
a 2.00 is the reference category.
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Figure 3. (A) Correlations between DLCO% and Fe levels in EBC
of patients with sarcoidosis. (B) Correlation between TLC values
and Fe levels in EBC samples of patients with idiopathic pulmonary
fibrosis.
discriminant metallic elements, and Cu was nearly significant
(p = 0.056). The classification table showed that 96.4% of
the ILD patients were correctly classified (54/56), and again
87.9% of the controls (29/33) (table 4 and figure 4). When
the significant metallic elements were considered separately,
Ni showed the greatest sensitivity (87.5%) and specificity
(63.6%).
Table 4. (A) Classification of cases by binary logistic regression
analysis. The patients with IPF, NSIP or sarcoidosis were
considered as a single group. (B) The significance of each metallic
element estimated by binary logistic regression analysis.
(A)
Predicted
Observed ILD Controls Percent correct
ILD 54 2 96.4%
Controls 4 29 87.9%
(B)
0 = IPF, NSIP
and sarcoidosis;
1 = controls Significance
Co 0.015
Mo 0.381
Zn 0.029
Cu 0.056
Si 0.026
Fe 0.474
Cr 0.999
Ni 0.002
Se 0.021
The probability of belonging to a given group calculated
by means of logistic regression was also used as a discriminant
variable in a ROC distinguishing controls and the ILD groups
as a whole (figure 5). Although the area under the ROC was
0.978 (95% CI 0.56–1) and therefore significantly different
from 0.5, a cut-off point of 0.407 maximized the sum of
sensitivity and specificity: sensitivity was 0.964 (95% CI
0.876–0.995) and specificity 0.909 (95% CI 0.756–0.980).
Drug treatment for other ILD patients were constituted
by oral corticosteroids alone (20 patients: 5 IPF, 9 NSIP
5
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Figure 4. Classification of cases by means of binary logistic regression analysis.
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Figure 5. ROC curve. The probability of belonging to a given
group (interstitial diseases or control) calculated by means of
logistic regression was used as a discriminant variable in the ROC
curve. The red arrow represents the cut-off point that maximized the
sum of sensitivity and specificity
(This figure is in colour only in the electronic version)
and 6 sarcoidosis) or in association with immunosuppressive
treatment (8 patients: 3 IPF, 4 NSIP and 1 sarcoidosis) or in
combination with hydroxychloroquine sulfate (3 sarcoidosis);
two patients were treated with pirfenidone (2 IPF) and two with
N-acetylcysteine (2 IPF). No differences in EBC metal levels
were observed when patients were classified according to drug
intake, nor differences were observed when ILD patients were
classified according to each disease severity.
Discussion
The results of this study show that there are only small overall
differences in the EBC levels of a number of metallic elements
among patients with IPF, NSIP or sarcoidosis, and no pattern is
capable of distinguishing them with a high degree of sensitivity
and specificity. However, a pattern of pneumotoxic (Si, Ni) and
essential elements (Zn, Se and, perhaps Cu) with the addition
of Co distinguished the patients with ILDs from healthy non-
smokers with relatively high degrees of sensitivity (96.4%) and
specificity (90.9%). The results were much more modest when
the individual elements were considered separately, despite the
significant between-group differences in their levels.
The EBC samples of all of the ILD patients contained
higher levels Ni, Cr and Si than those of the controls, and
those of the patients with IPF or sarcoidosis had lower levels
of Co. Furthermore, all of the ILD patients showed lower
levels of Cu and Se than the controls, and the patients with IPF
or NSIP had lower levels of Fe.
We have previously assessed the elemental composition of
EBC in patients with chronic obstructive pulmonary disease
(COPD) or asthma, as well as in healthy smokers and non-
smokers [21]. The COPD patients showed higher levels of
Al, Pb and Cd than the healthy non-smokers, and lower levels
of Cu and Fe, and the patients with asthma had lower levels
of Fe than the healthy non-smokers and higher Ni levels than
the healthy smokers. There were also differences between
the smokers and ex-/non-smokers in the COPD group: the
former had higher levels of Pb and Cd, and in comparison
with the healthy non-smokers, the latter had higher levels of
Pb, Cd and Al. We therefore assumed that the increased
levels of the three metallic elements in the COPD patients
were probably related to cumulative long-term exposure to
tobacco smoke (88% of the COPD patients were current or ex-
smokers) or environmental exposure to pneumotoxic metals,
and that the lower levels of Cu and Fe due to the metal
depletion involved in the anti-oxidant responsive element. As
inflammation and oxidative stress are common in ILDs and
other pulmonary diseases, it is not surprising that, like those
with COPD or asthma in our previous study, the ILD patients
in this study had lower levels of Cu and Fe. However, ILDs
have specific pathological mechanisms and histopathological
features that may explain the difference in the EBC levels of
some pneumotoxic metals.
Furthermore, the ILD patients in this study were all
ex-smokers or non-smokers, and we did not observe any
confounding effect of smoking on their EBC levels of metallic
elements. Consequently, Al, Cd and Pb were completely
unaffected by disease status in comparison with the controls
(Cd was almost always below the LOD). In contrast, the EBC
levels of other pneumotoxic metals (Ni, Cr and Si) were higher
in the ILD patients, thus indicating that they were probably
different from those of the COPD and asthmatic patients as a
result of different exposure to tobacco smoke. Further studies
are in progress in an attempt to identify different EBC patterns
of pneumotoxic metallic elements in patients with different
pulmonary diseases.
The fact that the levels of some metallic elements (Ni,
Cr and Si) were higher in our ILD patients than in the
6
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healthy controls may be due to their greater persistence at the
pulmonary level. Despite the differences between IPF, NSIP
and sarcoidosis, interstitial fibrosis is common to all ILDs
and could make the removal of metals difficult. Structural
alterations in the pulmonary interstitium reduce gaseous
exchange and this is reflected in the decreased DLCO levels
typical of ILD (and also found in our patients). Moreover,
these metals may be retained in the lungs for many years after
exposure has ceased.
Furthermore, published data from mineral microanalyses
of lung tissue or pulmonary lymph nodes in patients with ILD
indicate that there is a possible association between IPF and
mineral dust such as silica/silicates, Al and Ni [34–36], and
this is partially in line with our results. In a case report about
a young man with ILD, who was exposed for many years to
metal dust as a grinder covering steel tools with hard metals,
analysis of a lung biopsy performed 4 years after the exposure
had ceased showed higher levels of W, Ta, Co, Cr and Ni than
those found in 17 control biopsies [37]. However, the data are
difficult to interpret in terms of causality because of the lack of
a clear and established etiology and, in our study, the difficulty
in obtaining quantitative measures of dose and the duration of
an exposure that occurred many years ago.
Chronic inflammation and the associated oxidative stress
are important mechanisms in the pathogenesis of ILD [38]. We
found that, in comparison with the controls, the ILD patients
had lower EBC levels of some of the transition elements (Cu,
Fe and Se) involved in the redox systems controlling oxidative
stress. It is probable that the reduction in these trace elements
was due to their pulmonary depletion as a result of chronic
oxidative stress and inflammation [21].
The assessment of occupational exposure to metals in our
patients was done with a questionnaire (commonly used in
Italy to assess occupational exposure to metals), as biological
monitoring would have been not possible as most of the
patients were retired. We acknowledge that the questionnaire
may have limitation, especially when previous and possible
old exposures have to be assessed; this is why we proposed
the EBC metal analysis as a new tool to assess lung metal
burden in previously exposed patients.
To the best of our knowledge, there are no other studies
of metals in the EBC of patients with ILD, but Bargagli
et al [39] have recently assessed the concentrations of some
metals in BAL samples taken from patients with sarcoidosis,
IPF or Langerhan cell histiocytosis, and compared them with
the levels observed in healthy (smoking and non-smoking)
controls. The levels (given in micrograms per liter) varied
widely but were one to two orders of magnitude higher than
our EBC results, as can be expected because of the greater
dilution of non-volatile substances in EBC in comparison with
tissues, broncho–alveolar lining fluid and other biological
fluids; however, they were lower than the factor of 1000–
10 000 supposed for the dilution of EBC as compared with
blood. Unlike us, the authors found significantly lower levels
of Mn in their patients than in the controls, and lower levels of
both Zn and Cr in the patients with IPF, which they assumed to
be due to oxidative stress or clearance mechanisms. EBC and
BAL data are difficult to be compared, as correlations between
biomarkers in the two matrixes are generally poor [40].
We also found that the EBC pattern of metallic elements,
which was significantly different in the controls and ILD
patients, distinguished the two groups with a relatively high
degree of sensitivity (96.4%) and specificity (90.9%), though
individual elements were much less diagnostic, despite the
significant differences between groups in their levels.
One limitation of this study is the relatively small sample
size, which is explained by the low prevalence of ILD in
the general population. Given this low prevalence, it would
seem to be more appropriate to use analyses of the elemental
composition of EBC to rule out rather than confirm ILD in
subjects with suspect symptoms. Therefore, our findings
require validation in larger clinical studies. The findings
of this study could be improved by evaluating other ILDs
in order to verify whether there are any differences in the
EBC levels of metallic elements that may reflect differences in
pathological conditions that would be useful in distinguishing
patients with similar diseases. Furthermore, due to still
unknown mechanisms leading to EBC formation and possible
environmental confounding factors, it is not possible to define
reference values from healthy subjects; thus a pattern of
relative changes rather than absolute concentration should be
considered.
In conclusion, assessing the elemental composition of
EBC in patients with different ILDs seems to provide useful
information. We found higher levels of Ni, Cr and Si in
ILD patients than in controls, and lower levels of some trace
elements involved in the oxidant/anti-oxidant balance; this
depletion may be due to the oxidative stress and chronic
inflammation characterizing ILDs. Furthermore, the pattern
of some metallic elements seemed to be able to differentiate
controls and patients.
The non-invasiveness of the EBC method makes it suitable
for patients with pulmonary diseases, although further studies
are required to confirm the usefulness of this approach
and to better understand the underlying pathophysiological
processes.
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